Advertisement
In the 2009 second quarter earnings conference call, the Company announcedthat seven of its generics entered China's EDL. These seven medicines arebranded generics, which are currently manufactured with significant sales orlarge market potential. The other generics comprising the forty-two medicinesare seldom manufactured or have had insignificant sales in recent years.
Advertisement
The EDL issued by the MOH consists of 307 essential medicines that will begiven priority for basic healthcare. All of these medicines will be includedin the National Medical Insurance Catalog. The insurance reimbursement rate ofthese medicines will be higher than other medicines. Simcere is one of China'spharmaceutical companies with the largest number of generics in China's EDL.
Mr. Jinsheng Ren, Chairman and Chief Executive Officer of SimcerePharmaceutical Group, commented, "We are delighted to have forty-two ofSimcere's generics included in China's Essential Drug List. While maintainingour focus on first-to-market and innovative drugs, we will evaluate marketopportunities to update our strategy in generics sales to leverage theopportunities presented by the Essential Drugs List. We are confident thatSimcere will benefit from China's ongoing healthcare reform over themid-to-long term."
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leadingmanufacturer and supplier of branded generic and innovative pharmaceuticals inChina. In recent years, Simcere has been focusing its strategy on thedevelopment of innovative pharmaceuticals and first-to-market generics, andhas introduced an innovative anti-cancer medication Endu, a first-to-marketmedication Sinofuan, and first-to-market generics such as Bicun and Anxin.Simcere manufactures and sells anti-infective medication, anti-cancermedication and stroke management medication. Simcere concentrates its researchand development efforts on the treatment of diseases with high incidenceand/or mortality rates and for which there is a clear demand for moreeffective pharmacotherapy such as cancer, strokes, orthopaedics and infectiousdiseases. For more information about Simcere Pharmaceutical Group, pleasevisit http://www.simcere.com .
SOURCE Simcere Pharmaceutical Group
